论文部分内容阅读
目的:探讨LAK细胞和白介素Ⅱ配合化疗药物支气管动脉灌注治疗晚期肺癌的价值。方法:将40例晚期肺癌随机分为两组:LAK细胞和白介素Ⅱ配合化疗药物支气管动脉灌注20例为观察组;单纯化疗药物支气管动脉灌注20例为对照组。对两组病例的疗效、生存率和生活质量分别作x2检验,进行对照分析。结果:观察组首次治疗的近期疗效50％（10/20）,与对照组30％（6/20）比较,差异无显著性（x2=1.67,P>0.05）;但观察组1年生存率95％（19/20）,与对照组45％（9/20）比较,有高度显著性差异（x2=11.90,P<0.01）,且观察组较对照组生活质量明显提高（P<0.01）。结论:LAK细胞和白介素Ⅱ配合化疗药物支气管动脉灌注,可能是晚期肺癌较为有效的治疗方法。
Objective: To investigate the value of LAK cells and interleukin II combined with chemotherapeutic agents in the treatment of advanced lung cancer with bronchial arterial infusion. Methods: 40 cases of advanced lung cancer were randomly divided into two groups: LAK cells and interleukin II combined with chemotherapeutic agents in 20 cases of bronchial arterial infusion as the observation group; 20 cases of bronchial arterial infusion of chemotherapy drugs alone as control group. The x2 test was performed on the efficacy, survival rate and quality of life of the two groups of patients for comparative analysis. Results: The short-term efficacy of the first treatment in the observation group was 50% (10/20), compared with 30% (6/20) in the control group, the difference was not significant (x2=1.67, P>0.05); but the 1-year survival rate of the observation group 95% (19/20), compared with the control group 45% (9/20), there was a highly significant difference (x2 = 11.90, P <0.01), and the quality of life in the observation group was significantly higher than that in the control group (P <0.01) . Conclusion: LAK cells and interleukin II combined with chemotherapeutic agent bronchial arterial infusion may be a more effective treatment for advanced lung cancer.